Goldman Sachs analyst David Roman downgraded Baxter (BAX) to Neutral from Buy with a price target of $25, down from $37.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Cautious Outlook for Baxter International Amid Weaker MPT Performance and Revised Growth Expectations
- Baxter sees Q3 adjusted EPS 58c-62c, consensus 64c
- Baxter cuts FY25 adjusted EPS view to $2.42-$2.52 from $2.47-$2.55
- Baxter reports Q2 adjusted EPS 54c, consensus 61c
- BAX Earnings this Week: How Will it Perform?